Key result
Patients with metabolic syndrome had significantly lower adiponectin levels (13.03 vs 15.74 μg/mL, p=0.01) compared to those without, despite having similar adipose tissue mass and distribution.
Why the study?
To establish more efficient ways to prevent metabolic syndrome (MetS), a clearer understanding of its physiopathology and a defined adipokine profile alongside correlations with obesity parameters and biochemical markers were needed.
Cross-Sectional (n=104)
No
Absolute Event Rate: 13.03% vs 15.74%
p-value: p=0.01
In patients with similar adipose tissue mass and distribution, metabolic syndrome is associated with lower adiponectin levels and higher insulin resistance, while leptin levels correlate strongly with adipose tissue mass regardless of metabolic syndrome status.
Supports adiponectin as metabolic syndrome marker beyond adiposity; leaves open prognostic or therapeutic utility.
In order to establish more e fficient ways to prevent metabolic syndrome (MetS) in clinical settings, we need to thoroughly understand the physiopathology behind this cluster of risk factors for cardiometabolic di seases. The main point of focus concerning MetS still embraces the metabolic and secretory products of the abdominal adipose tissue. Our study aims to clearly define an adipokine profile for patients with MetS and assess possible correlations between obesity parameters, bi ochemical markers and adipokines. Material and methods: This is a cross-sectional study, elaborated over a period of two years, which involved 104 patients divided into 2 groups: with MetS and without MetS. Patients were considered as having MetS if they presented WC > 88 cm (women) / 104 cm (men) and more than one criterion of the following: glucose 100 mg/dL, HDL < 40 mg/dL (men) / < 50 mg/dL (women), TG 150 mg/dL, SBP/DBP 130/85 mmHg. Dual-Energy X-ray Absorptiometry (DEXA) was performed to assess adipose tissue distribution. All patients underwent clinical and paraclinical evaluation, including the measurements of insulin, adiponectin and leptin. Results: Leptin levels present a strong and positive correlation with almost all obesity parameters evaluated, with or without MetS. The strongest correlation is observed for trunk fat percentage (without MetS: r=0.648, p<0.001; with MetS: r=0. 723, p<0.001). In the group of patients without MetS adiponectin level is not associated with fat percentages, whereas in the group of patients with MetS ad iponectin reports a weak and positive correlation between total fat, arms fat and legs fat pe rcentages. Adiponectin is negatively correlated with HOMA-IR and insulin in both groups, suggesting that insulin resistance is linked to the change in adiponectin levels. Pati ents that present MetS also report an association between HDL and adiponectin (r=0.280, p=0.02). Conclusions: Patients with MetS that did not follow prior treatment for any chronic disease and are characterized by similar adipose tissue percentage and dist ribution, report the following: lower adiponectin levels than patients without MetS, but still a positive association with HDL; no modification in leptin levels compared to patients without MetS; negative co rrelation between adiponectin and insulin resistance; strong association between leptin and adipose tissue mass.
No takes yet. Share an insight, caveat, or question.
Ivona Mitu (2022) conducted a cross-sectional in Metabolic syndrome (n=104). Metabolic syndrome vs. Without metabolic syndrome was evaluated on Serum adiponectin levels (μg/mL) (p=0.01). Patients with metabolic syndrome had significantly lower adiponectin levels (13.03 vs 15.74 μg/mL, p=0.01) compared to those without, despite having similar adipose tissue mass and distribution.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: